Home › Funds › Parkman Healthcare Partners LLC › BCRX
Parkman Healthcare Partners LLC position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
Parkman Healthcare Partners LLC reported holding 1,624,279 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$16.2M, representing 1.66% of its reported portfolio and ranking #24 among its reported holdings. Parkman Healthcare Partners LLC has disclosed BCRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's BCRX position evolved
Parkman Healthcare Partners LLC first disclosed a stake in BCRX in Q2 2024 at 400,448 shares (US$2.5M). The position peaked in Q1 2026 at 1,708,099 shares, worth US$16.3M. Across 9 filings, Parkman Healthcare Partners LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,624,279 shares valued at US$16.2M — a reduction of -83,820 shares quarter over quarter.. Notable position changes include a 53% trim in Q4 2024 (shares were roughly flat over the following quarter), a 361% increase in Q1 2025 (shares rose 19% over the following quarter), a 90% increase in Q1 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 400.45K | $2.47M | New |
| Q3 2024 | 464.05K | $3.53M | Add |
| Q4 2024 | 216.88K | $1.63M | Reduce |
| Q1 2025 | 1.00M | $7.50M | Add |
| Q2 2025 | 1.01M | $9.03M | Add |
| Q3 2025 | 1.01M | $7.69M | Hold |
| Q4 2025 | 900.06K | $7.02M | Reduce |
| Q1 2026 | 1.71M | $16.26M | Add |
| Q2 2026 | 1.62M | $16.24M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M sh · $25.23M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M sh · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M sh · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M sh · $18.66M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held BCRX?
Parkman Healthcare Partners LLC has disclosed BCRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is Parkman Healthcare Partners LLC's current position in BCRX?
As of Q2 2026, Parkman Healthcare Partners LLC holds 1.62M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $16.24M, representing 1.66% of its reported portfolio and ranking #24.
Has Parkman Healthcare Partners LLC been buying or selling BCRX?
In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC reduced its position in BCRX. The position peaked in Q1 2026 at 1.71M shares.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.